BRCA2 and breast carcinoma: Despite the small sample size, the prospective nature of the analysis along with the ability to adjust for potential confounders suggests that RANKL is likely not a circulating biomarker of breast cancer risk among women with an inherited BRCA1 or BRCA2 mutation.